系统性红斑狼疮患者中羟氯喹和氯喹视网膜病变新危险因素的识别
这项病例对照研究(1:2)比较了48例出现羟氯喹或氯喹视网膜病变的系统性红斑狼疮患者与96例无病变对照,匹配性别、用药时长和诊断时年龄。多变量分析显示,合用SSRI/SNRI、抗磷脂综合征、血[HCQ]/[DCQ]比值<7.2和皮肤光型≥4与视网膜病变独立相关,而日剂量、血[HCQ]浓度和体重指数未显示关联。
要点
- 合用SSRI/SNRI、抗磷脂综合征、血[HCQ]/[DCQ]比值<7.2和皮肤光型≥4是新的独立危险因素。
- 日羟氯喹剂量、血[HCQ]浓度和体重指数未显示与视网膜病变独立相关。
- 血[HCQ]/[DCQ]比值<7.2的OR为8.4(95%CI 2.7-30.8),皮肤光型≥4的OR为5.5(95%CI 1.4-26.5)。
核心结论
- 该病例对照研究识别出血[HCQ]/[DCQ]比值、合用SSRI/SNRI、皮肤光型≥4和抗磷脂综合征为羟氯喹或氯喹视网膜病变的新危险因素。
研究设计与样本
- 病例对照研究(1:2),纳入48例出现羟氯喹或氯喹视网膜病变的系统性红斑狼疮患者为病例,96例无视网膜病变的系统性红斑狼疮患者为对照。
- 对照按性别、羟氯喹和/或氯喹治疗时长(±1年)及系统性红斑狼疮诊断时年龄(±5岁)匹配。
主要发现
- 合用SSRI或SNRI与视网膜病变独立相关(OR 6.6,95%CI 1.2-40.9,p<0.01)。
- 抗磷脂综合征与视网膜病变独立相关(OR 8.9,95%CI 2.2-41.4,p<0.01)。
- 血[HCQ]/[DCQ]比值<7.2与视网膜病变独立相关(OR 8.4,95%CI 2.7-30.8,p<0.01)。
- 皮肤光型≥4与视网膜病变独立相关(OR 5.5,95%CI 1.4-26.5,p=0.02)。
- 日羟氯喹剂量、血[HCQ]浓度和体重指数未显示与视网膜病变独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3-8 % of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease. However, those factors cannot explain the entire risk of developing antimalarial retinopathy. OBJECTIVE: This study was undertaken to identify new risk factors associated with HCQ or CQ retinopathy (QRNP) in systemic lupus erythematosus (SLE) patients. METHODS: This case-control (1:2) study compared SLE patients with QRNP (cases) to those without (controls). Controls were matched for sex and known QRNP risk factors: HCQ and/or CQ treatment duration (±1 year) and age (±5 year) at SLE diagnosis. RESULTS: Forty-eight cases were compared to 96 SLE controls. Multivariable logistic-regression analysis retained the following as independent determinants significantly associated with QRNP: concomitant selective serotonin-reuptake inhibitor (SSRI) or serotonin- and norepinephrine-reuptake inhibitor (SNRI) intake (OR [95 % confidence interval] 6.6 [1.2 to 40.9]; p < 0.01); antiphospholipid syndrome (OR=8.9 [2.2 to 41.4] p < 0.01); blood hydroxychloroquine/desethylchloroquine concentration ([HCQ]/[DCQ]) ratio <7.2 (OR 8.4 [2.7 to 30.8]; p < 0.01) or skin phototype ≥4 (OR 5.5 [1.4 to 26.5]; p = 0.02), but not daily HCQ dose, blood [HCQ] or body mass index. CONCLUSION: The results of this case-control study identified blood [HCQ]/[DCQ] ratio, concurrent SSRI/SNRI therapy, skin phototype ≥4 and antiphospholipid syndrome as new risk factors for QRNP.
引用
- Trefond L, Lhote R, Mathian A, et al. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients. Semin Arthritis Rheum. 2024. PMID: 38394986. doi:10.1016/j.semarthrit.2024.152417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。